Clinical Research Gallery Manager
Resume:
Curriculum Vitae
Justin Deck
949-***-**** (cellular) adr9bt@r.postjobfree.com (email) https://www.linkedin.com/in/justin-deck-58a6a21b/ (LinkedIn) PROFESSIONAL PROFILE
Justin has more than 20 years of experience in all aspects of clinical research, clinical trials and regulatory strategy across academic, industry, CRO, and site settings. Prior to joining Tilda Research, he was the founder and CEO of Alliance Research Centers - a multi-site, multi-specialty site management organization in Southern California. As Founder and CEO of Alliance Research Centers, Justin successfully oversaw all operations, strategy, and funding rounds to ensure scale and success throughout its three offices and an exclusive network of 225 providers.
I am passionate about clinical research and the opportunity to transform modern healthcare. I stay current on the latest industry and healthcare trends, while creating innovative partnerships in an industry ripe for growth and change.
My professional experience has empowered me to present at numerous conferences and advise many industry partners (from entrepreneurs to VPs, to C-Level Executives) in their entry to market and growth strategies. AREAS OF EXPERTISE
» Executive Leadership
» Project Management
» Documentation & Deliverables
» Process Improvement (PI)
» Physician Relations
» Research Coordination
» Database Maintenance
» Data Entry & Outputs
» Business Development
» Strategic Partnerships
» Remote Work & Online Collaboration
» Research Methodology Background
» Written & Verbal Communication
» Quality Assurance / Quality Control
» Contract Negotiation
Education & Training:
Undergraduate: University of Southern California
Keck School of Medicine
Los Angeles, CA
Bachelor of Science, Health Promotion and Disease Prevention December 2003
Internship: Irvine Cancer Institute
Kenneth Tokita, MD – Oncologist
Irvine, CA
May 2002 to December 2003
Post-baccalaureate / University of California, Irvine - School of Medicine Internship Irvine, CA
David K. Imagawa MD PhD
Professor of Clinical Surgery
Chief Division of Hepatobiliary and Pancreas Surgery/Islet Cell Transplantation
May 2002 to December 2003
Version: 18JUL2022
Page 2 of 18
Past Employment:
2019 – 2022
Tilda Research
Chief Clinical Officer
18600 MacArthur Blvd, Suite 360
Irvine, CA, 92612
Provided strategic leadership and oversight of all corporate programs and provided clinical supervision to core clinical and engineering staff. Developed and implemented goals and objectives of the Company to drive a culture of compliance and compassionate care on all levels. Supported quality, compliance, business development, clinical operations, and corporate fundraising activities. 2018 – 2019
Alliance Research Centers
Chief Executive Officer
24012 Calle de la Plata, Suite 230
Laguna Hills, CA 92653
Provided corporate leadership to the Company, its Shareholders, and employees. Worked through Shareholder investment and divestment activities and ultimately secured external capital through Family Office to support further growth. Ultimately responsible for the oversight, purchase, and acquisition of Alliance Research Centers by Tilda Research in November of 2019. 2012 – 2018
Alliance Research Centers
Founder and Chief Clinical Officer
24012 Calle de la Plata, Suite 230
Laguna Hills, CA 92653
Procured seed money to establish an independent research center in Southern California. Identified and aligned with key medical professionals with similar interests in conducting clinical research within their private community practices. Exclusive provider base of one office with seven physicians in 2012 and grew to 225 physicians by 2019. Annual revenues of the Company grew 50% 2012 through 2015, then 40% 2015-2016, and 30% 2016 to 2018.
2012 - 2019
Alliance Research Centers
Certified Clinical Research Coordinator
24012 Calle de la Plata, Suite 230
Laguna Hills, CA 92653
Procured clinical studies, facilitated enrollment of patients, lead and train clinical research coordinators and served as the main liaison between Sponsors, physicians, staff, IRBs and the U.S. Food and Drug Administration. etc. Established corporate SOPs, work instructions, and adoption of clinical trial management system to efficiently manage all corporate activities across three independent sites. Successfully completed seven FDA inspections for routine, pivotal, studies where Alliance Research Centers resulted in the top three centers for overall study enrollment. 2004 – 2010
Caring Clinical Research Corporation
Sr. Manager, Clinical Operations
(Formerly known as Accurate Clinical Trials, Inc.) 23961 Calle de la Magdalena, Suite 305
Laguna Hills, CA 92653
Version: 18JUL2022
Page 3 of 18
Past Employment (Continued):
2004 - 2012
South Orange County Surgical Medical Group
Clinical Research Consultant
24411 Health Center Drive, Suite 350
Laguna Hills, CA 92653
6/1999 – 9/1999
South Orange County Endocrinology
Research Assistant / Office Assistant
Laguna Hills, CA
1995-2004
Plaza Art Gallery
Art and Production Gallery Manager
San Juan Capistrano, CA
Board / Advisory Positions:
2018 – Present
Murrieta Genomics
Murrieta, CA
Strategic clinical advisor to Murrieta Genomics and incubator companies at the Murrieta Innovation Center. Support, participate, and advise at pitch competitions throughout California. 2018 – Present
City of Murrieta – Department of Economic Development Murrieta, CA
Strategic clinical advisor to City of Murrieta and Department of Economic Development in their pursuit of biotech innovation in Southwest Riverside County, California. 2012 – Present
WCG-IRB
Institutional Biosafety Committee
Member
2020 – 2021
RuleOut.Org
Coalition of healthcare professionals addressing the shortage of testing reagents, antigen-based tests and testing facilities to diagnose SARS-COV-2.
San Diego, CA
2012 – 2014
Strategic Advisor (eSource and eReg Assets)
Veeva Systems
Pleasanton, CA
Version: 18JUL2022
Page 4 of 18
Board / Advisory Positions (Continued):
2012 – 2013
BWTC Holding, Inc.
Re: CAS-001 Product Development, Market Strategy, Clinical Testing Nashville, TN
2006 – 2010
Memorial Health Services Research Council
Saddleback Memorial Medical Center
Project Evaluation Committee
Sub-Committee to the Memorial Health Services Institutional Review Board Member at Large
Accelerator / Incubator Experience:
2018 – 2019
OctaneOC
Octane is a convening organization of the Southern California technology and medical technology business ecosystem by connecting people, resources and capital. Clinical Research Training and Certification:
Association of Clinical Research Professionals
Certified Clinical Research Coordinator
2006 – Present
“Preparing Research Organizations for Digital Tools and Part 11 Compliance.” Kinetiq, 1501 Fourth Avenue, Suite 800, Seattle, WA 98101. March 19th, 2018.
“2017 in Review - How Legal and Regulatory Changes Impact Your Research.” Kinetiq, 1501 Fourth Avenue, Suite 800, Seattle, WA 98101. December 19th, 2017.
“Implementing the New Common Rule—Practical Advice for Research Organizations.” Kinetiq, 1501 Fourth Avenue, Suite 800, Seattle, WA 98101. September 12th, 2017.
“Strategies for Implementing the NIH Single IRB (sIRB) Mandate.” Kinetiq, 1501 Fourth Avenue, Suite 800, Seattle, WA 98101. August 29th, 2017.
“Adopting eConsent in Research: Security, Privacy, and Regulatory Considerations.” Kinetiq, 1501 Fourth Avenue, Suite 800, Seattle, WA 98101. July 10th, 2017.
“How eConsent Optimizes Research for Sponsors and CROs.” Kinetiq, 1501 Fourth Avenue, Suite 800, Seattle, WA 98101. February 2nd, 2017.
“Biospecimens Today & Tomorrow!” Kinetiq, 1501 Fourth Avenue, Suite 800, Seattle, WA 98101. March 29th, 2016.
“eConsent for Research: Considerations in Implementation and IRB Review.” Quorum Review IRB. Webinar. June 20th, 2013. Webinar ID: 841-768-446
“What is an Unanticipated Problem … and What Does This Mean for My SAEs?” Presented by: Bonnie J. Brookshire, CIP, Sr. Director of Compliance Compass IRB. August 7th, 2012. Version: 18JUL2022
Page 5 of 18
Clinical Research Training and Certification (Continued):
“New FDA Guidance for Industry: Oversight of Clinical Investigations.” Quorum Review IRB. Webinar. May 1st, 2012. ID: 974-536-226
“Research and HIPAA Recruitment Consent and Beyond.” Quorum Review IRB. Webinar. April 10th, 2012. ID: 378-322-598
“Using Electronic Consent and Technologies to Facilitate and Improve the Research Process - Regulatory and IRB Considerations.” Quorum Review IRB. Webinar. November 30, 2011. Webinar ID: 693-243- 238
“Reducing the Barriers to the Conduct and Oversight of Clinical Trials: A Case Study.” Copernicus Group Independent Review Board. Webinar. October 18th, 2011. Webinar ID: 175-967-914
“Using Social Media in Research: Regulatory and IRB Considerations” Quorum Review Independent Review Board. Webinar. June 2nd, 2011
“Safety Reporting to the Institutional Review Board (IRB): Understanding Recent Guidance.” Copernicus Group IRB. Webinar. May 4th, 2011
“The FDA as a Public Health Agency.” ACRP-APPI Global Conference hosted Joshua M. Sharfstein MD. April 26th, 2010
Mayo Clinic – Mayo Medical Laboratories
Record of Training for the Shipping of Category A, Infectious Substance Affecting Humans; Category B, Biological Substance
Certification Dated 2006 - Present
Quintiles Transnational's online educational program titled “Introduction to Clinical Drug Development Process: ICH/FDA Good Clinical Practice for Clinical Trial Sites.” Certification Dated May 2010.
Purdue Pharma – Preparing for the FDA
Webinar
October 30th, 2009
BIMO Inspections – What is the FDA Really Looking At? Audio Conference
January 8th, 2008
Association of Clinical Research Professionals
Certified Clinical Research Coordinator
March 2006 to Present
MemorialCare: HIPAA Security Training Online
Saddleback Memorial Medical Center, Department#74200 Completed on June 10th, 2005.
Conference: The Informed Consent Process at MemorialCare by Harris Stutman MD and Allison Kennon-Frink of Memorial Health Services Research Council dated June 7th, 2005. Version: 18JUL2022
Page 6 of 18
Clinical Research Training and Certification (Continued): Conference: Investigator and Coordinator Training for Medical Research sponsored by the Western Institutional Review Board and the University of Rochester Medical Center. Certificate dated February 7th, 2005.
Clinical Research Coordinator training 6-04 to 9-04 with Accurate Clinical Trials, Inc. Human Participants Protection Education for Research Teams sponsored by the National Institutes of Health (NIH). Certificate dated July 7th, 2004 (Renewed in 2006, 2008, 2010, 2012). HIPAA online training: Confidentiality and Protected Health Information. University of California, Irvine. Under Dr. David K. Imagawa. 2003.
Conference: Four Ways to Improve the Informed Consent Process by Mark Hochhauser, Ph.D. dated July 9th, 2004.
Safe handling and Packaging of Dangerous Goods—Saf-T-Pak Inc. Training. Certification dated August 31st, 2004 (Renewed 2006 and 2008)
Mayo Clinic – Mayo Medical Laboratories – Training for the shipping of Category A Infectious Substance Affecting Humans, Category B, Biological Substances (2010, renewed 2012, 2014, 2016, 2018, 2020)
Clinical Research Experience:
Tilda Research – Irvine
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease
(TRAILBLAZER-ALZ 3)
Tilda Research – Irvine
Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli
Tilda Research – Irvine
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology (PROTECT)
Tilda Research – Irvine
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects (APOLLOE4) Tilda Research – Irvine
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER- ALZ 2)
Tilda Research – Irvine
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND) Tilda Research – Irvine
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
Version: 18JUL2022
Page 7 of 18
Clinical Research Experience (Continued):
Tilda Research – Irvine
Clinical Trial Multi-analyte Blood Test (CLiMB)
Tilda Research – Irvine
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare) Tilda Research – Irvine
Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC. Alliance Research Centers – Laguna Hills
A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Pimecrolimus Cream, 1% and Reference Listed Elidel®
(Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis
Alliance Research Centers – Laguna Hills
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo UK FINCO's lvermectin Cream, 1% to Galderma Laboratories, Soolantra • Cream {lvermectin) Cream, 1%, and Both Active Treatments to a Vehicle Control in the Treatment of Inflammatory Lesions of Rosacea
Alliance Research Centers – Laguna Hills
A Phase 2 Study of Poziotinib in Patients with HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC
Alliance Research Centers – Laguna Hills
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block with EXPAREL for Postsurgical Analgesia in Subjects Undergoing Total Shoulder Arthroplasty or Rotator Cuff Repair Alliance Research Centers – Laguna Hills
A Study Determining Variances in Ostomy Skin Conditions and The Economic Impact (ADVOCATE) Alliance Research Centers – Laguna Hills
Phase 2 Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) vaccine vs Unloaded YCWP + DC in State III and IV (Resected) Melanoma to Prevent Recurrence
Alliance Research Centers – Laguna Hills
A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Simple Bunionectomy
Alliance Research Centers – Laguna Hills
A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy
Version: 18JUL2022
Page 8 of 18
Clinical Research Experience (Continued):
Alliance Research Centers – Laguna Hills
A Phase 3, Randomized, Double-Blind, Active-Controlled, Multicenter, Safety and Pharmacokinetic Study of HTX-011 via Local Administration in Multiple Surgical Procedures Alliance Research Centers – Laguna Hills
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF XXXXXXX (XXXXXXX) COMPARED TO PIPERACILLIN/TAZOBACTAM IN THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING ACUTE PYELONEPHRITIS, IN ADULTS Alliance Research Centers – Laguna Hills
Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXXXXXX in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) Alliance Research Centers – Laguna Hills
Randomized, Double-Blind, Placebo-Controlled, 2-Arm, 6-Month, Brain Imaging and Safety Study of Leuco-methylthioninium bis(hydromethanesulfonate) (LMTM) in Subjects with Mild Alzheimer’s Disease
Alliance Research Centers – Laguna Hills
A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study with a 24-week Extension Period to Evaluate the Safety and Efficacy of XXXXXXXXXXX 10 mg Daily in Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on a DPP-4 inhibitor (Sitagliptin) Alone or in Combination with Metformin Alliance Research Centers – Laguna Hills
Twice-daily oral direct thrombin inhibitor XXXXXXX XXXXXXXX in the long- term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism, RE-SONATE
Alliance Research Centers – Laguna Hills
Bupivacaine Effectiveness and Safety in XXXXXXX Trial Alliance Research Centers – Laguna Hills
A phase IIIb, open-label, single-arm, multicenter study to assess the immunogenicity of the r-hGH liquid multidose formulation (XXXXXXXXXXXXXX) when administered to male and female adults with documented growth hormone deficiency (GHD)
Alliance Research Centers – Laguna Hills
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of XXXXXXXXXXXXX Versus Sitagliptin in the Treatment of Subjects with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy Alliance Research Centers – Laguna Hills
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel- group Study of Oral XXXXXXXXXXXXX (XX) for the treatment of Opioid- Induced Constipation (OIC) in Subjects with Chronic, Non-Malignant Pain
Version: 18JUL2022
Page 9 of 18
Clinical Research Experience (Continued):
Alliance Research Centers – Laguna Hills
Use of Oral XXXXXXXXXXXXX (XXXXXXXXX) in patients with chronic non-malignant pain who have opiate induced constipation.
Alliance Research Centers – Laguna Hills
Longitudinal Cohort Study of Resource use and Cost of Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease in the United States (GERAS-US) Alliance Research Centers – Laguna Hills
A 24-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer’s Disease
(The AMARANTH Study)
Alliance Research Centers – Laguna Hills
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study) Alliance Research Centers – Laguna Hills
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants with Mild to Moderate Alzheimer's Disease
(AD) with an Optional 26-Week Open-label Extension Alliance Research Centers – Laguna Hills
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole (OPC 34712) in the Treatment of Subjects with Agitation Associated with Dementia of the Alzheimer’s Type Alliance Research Centers – Laguna Hills
A Single-Country, Multicenter, Single-Arm Study of the Effects of XXXXXX on Spermatogenesis and Testicular Function
Alliance Research Centers – Laguna Hills
A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF XXXXXXX IN SUBJECTS WITH CRITICAL LIMB ISCHEMIA
Alliance Research Centers – Laguna Hills
Randomised Evaluation of XXXXX XXXXXX Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral antIcoagulation sTrategy (The XXXXXXX Trial) Alliance Research Centers – Laguna Hills
XXXXXXX Registry Patient and Provider Assessment of Lipid Management Registry Alliance Research Centers – Laguna Hills
Phase II Trial of Combination Immunotherapy with XXXXXXX + GM-CSF (XXXXXXX) and Trastuzumab in high-risk HER2+ Breast Cancer Patients Alliance Research Centers – Laguna Hills
Combination immunotherapy with Herceptin and the XXXXXXX in low and intermediate HER2- expressing breast cancer patients to prevent recurrence Version: 18JUL2022
Page 10 of 18
Clinical Research Experience (Continued):
Alliance Research Centers – Laguna Hills
“PRESENT”: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with XXXXXXX Treatment Alliance Research Centers – Laguna Hills
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XXXXXXX Bupivacaine Implant (300mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty
Alliance Research Centers – Laguna Hills
Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXXXXXX as Adjunctive Therapy in Subjects with Signs and Symptoms of Osteoarthritis of the Hip or Knee
Alliance Research Centers – Laguna Hills
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of XXXXXXX in Young Adult Patients with Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C
Alliance Research Centers – Laguna Hills
A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Repeated-Dose, Multicenter Study to Compare Intravenous and Oral XXXXXXX for the Treatment of Acute Moderate to Severe Pain in Combination with Patient-Controlled Analgesia with Morphine in Adults Following Elective Total Knee Arthroplasty
Alliance Research Centers – Laguna Hills
A Phase III Study Evaluating the Efficacy and Safety of XXXXXXX (XXXXXXX) Compared to Placebo and Midazolam in Patients Undergoing Bronchoscopy
Alliance Research Centers – Laguna Hills
A Study Evaluating the Safety and Efficacy of XXXXXXX (XXXXXXX) Compared to Placebo and Midazolam in ASA III and IV Patients Undergoing Colonoscopy Alliance Research Centers – Laguna Hills
A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF XXXXXXX IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS
Alliance Research Centers – Laguna Hills
Multicenter, Double-Blind, Placebo-Controlled Study of XXXXXXX (XXXXXXX) Administered Immediately after Radiocephalic Arteriovenous Fistula Creation in Patients with Chronic Kidney Disease Alliance Research Centers – Laguna Hills
Efficacy, Immunogenicity, and Safety Study of XXXXXXX in Subjects at Risk for C. difficile Infection Alliance Research Centers – Laguna Hills
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of XXXXXXX (200 mg BID) for 10 days Compared with Fidaxomicin (200 mg BID) for 10 days for the Treatment of Clostridium difficile Infection (CDI) Version: 18JUL2022
Page 11 of 18
Clinical Research Experience (Continued):
Alliance Research Centers – Laguna Hills
A Randomized, Double-Blind, Dose-Finding, Placebo-Controlled, Phase II Multicenter Study of XXXXXXX in the Treatment of Chemotherapy Induced Neuropathic Pain Alliance Research Centers – Laguna Hills
A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXXXXXX (3.0 and 6.0 mg) in Patients with Chronic Idiopathic Constipation Alliance Research Centers – Laguna Hills
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of XXXXXXX as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Alliance Research Centers – Laguna Hills
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF XXXXXXX (XXXXXXX) COMPARED TO PIPERACILLIN/TAZOBACTAM IN THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING ACUTE PYELONEPHRITIS, IN ADULTS Alliance Research Centers – Laguna Hills
Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXXXXXX in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) South Orange County Endocrinology – Laguna Hills, CA A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study with a 24-week Extension Period to Evaluate the Safety and Efficacy of XXXXXXXXXXX 10 mg Daily in Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on a DPP-4 inhibitor (Sitagliptin) Alone or in Combination with Metformin South Orange County Surgical Medical Group – Laguna Hills Twice-daily oral direct thrombin inhibitor XXXXXXX XXXXXXXX in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism, RE-SONATE
South Orange County Surgical Medical Group – Laguna Hills Bupivacaine Effectiveness and Safety in XXXXXXX Trial South Orange County Endocrinology – Laguna Hills, CA A phase IIIb, open-label, single-arm, multicenter study to assess the immunogenicity of the r-hGH liquid multidose formulation (XXXXXXXXXXXXXX) when administered to male and female adults with documented growth hormone deficiency (GHD)
Alliance Research Centers – Laguna Hills
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of XXXXXXXXXXXXX Versus Sitagliptin in the Treatment of Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy Version: 18JUL2022
Page 12 of 18
Clinical Research Experience (Continued):
Alliance Research Centers – Laguna Hills
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-group Study of Oral XXXXXXXXXXXXX (XX) for the treatment of Opioid-Induced Constipation (OIC) in Subjects with Chronic, Non-Malignant Pain
Alliance Research Centers – Laguna Hills
Use of Oral XXXXXXXXXXXXX (XXXXXXXXX) in patients with chronic non-malignant pain who have opiate induced constipation.
Alliance Research Centers – Laguna Hills
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL- TREATMENT GROUP, MULTICENTER EFFICACY AND SAFETY STUDY OF INTRA-ANAL APPLICATION OF XXXXXXXXXXX (10 MG) AS A 0.5% OINTMENT IN SUBJECTS WITH SYMPTOMATIC INTERNAL HEMORRHOIDS
Alliance Research Centers – Laguna Hills
A Long-Term Open-Label Safety Study of XXXXXXXXX XXXXX Controlled-Release Capsules with Flexible Dosing to Treat Subjects with Moderate to Severe Chronic Pain Alliance Research Centers – Laguna Hills
A RANDOMIZED, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH XXXXXXX ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Alliance Research Centers – Laguna Hills
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXXXXX XXXXXXXXXX Extended-Release Tablets (XXXXXXXXXX) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients with Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time Alliance Research Centers – Laguna Hills
A Long-Term Open-Label Safety Study of XXXXXXXXXXX XXXXXXXXXXX Controlled-Release Capsules with Flexible Dosing to Treat Subjects with Moderate to Severe Chronic Pain Alliance Research Centers – Laguna Hills
Two Approaches to Escalate XXXXXX Therapy in Patients with Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on Basal Insulin Therapy and Oral Agents Alone Alliance Research Centers – Laguna Hills
A Randomized, Double-Blind, Active-Controlled, 2-Arm, Parallel-Group, Multicenter Study, to Evaluate the Efficacy, Safety, and Tolerability of XXXXXXXXXX Versus Sitagliptin in the Treatment of Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy
Alliance Research Centers – Laguna Hills
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with XXXXXXXXXXX in type 2 diabetic patients after an Acute Coronary Syndrome
Version: 18JUL2022
Page 13 of 18
Clinical Research Experience (Continued):
Alliance Research Centers – Laguna Hills
A 24-week, multicenter, international, randomized (1:1), parallel-group, open-label, comparative study of XXXXXXXXXXX versus XXXXXXXXXX in insulin-naïve patients with Type 2 diabetes treated with oral agents and not adequately controlled, followed by a 24-week extension period with XXXXXXXXXXX for patients not adequately controlled with XXXXXXXXXX Alliance Research Centers – Laguna Hills
A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study with a 24-week Extension Period to Evaluate the Safety and Efficacy of XXXXXXXXXXXXX Daily in Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on a DPP-4 Inhibitor (XXXXXXXX) Alone or in Combination with Metformin Alliance Research Centers – Laguna Hills
Efficacy and Safety of XXXXXXXXXX in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy
Alliance Research Centers – Laguna Hills
An Open Label, Dose-Titration Investigation of the Pharmacokinetics, Metabolism and Safety of XXXXXXXXXXX Testosterone Transdermal Systems at doses of 2, 4 and 6 mg/day in Hypogonadal Men
Saddleback Memorial Medical Center, Clinical Research Coordinator A Phase 4, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of XXXXXXXX for the Management of Postoperative Ileus in Subjects Undergoing Radical Cystectomy Caring Clinical Research Corporation, Clinical Research Coordinator Protocol XXXXXXXX – Acute Otitis Media Study in Children Aged 6 Months to 12 Years Post- Tympanostomy Tube Insertion
Caring Clinical Research Corporation, Clinical
Contact this candidate